Gene Therapy Manufacturing Hurdle: Sponsors Unwilling To Share ‘Secret Sauce’
Executive Summary
US FDA’s Peter Marks says companies are not exchanging information about adenoviral factors, which is probably slowing down the field. He describes NIH's plans for a bespoke gene therapy consortium for vector generation and continued efforts for regulatory harmonization.
You may also be interested in...
Rare Cancer Development Consortium Moving Toward Target Selection
An upcoming public meeting will include a look at platforms before the first targets are chosen.
‘Pull Every Lever’: FDA’s Marks Worries Gene Therapies Could Falter Without Help To Lower Cost
CBER’s director says manufacturing and regulatory issues need to be resolved to ensure the gene therapy sector thrives.
IRA’s Orphan Drug Exemption Could Lead to More Off-Label Prescribing
Rare disease advocates also argue that the Medicare’s government drug price negotiation orphan drug exemption – which only applies when a drug has one orphan designation – will harm other government efforts aimed at more efficient drug development.